Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Methoxsalen + Phenytoin + Sirolimus + SM88 |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Methoxsalen | Deltasoralen | Methoxalen | ||
Phenytoin | Aleviatin | 5,5-Dwufenylohydantoina | ||
SM88 | SM-88|Racemetyrosine|Racemetirosine | SM88 is a modified tyrosine derivative that may interfere with protein synthesis, leading to oxidative damage and cell death in tumor cells (PMID: 31358523, PMID: 30929156). | ||
Sirolimus | Rapamune | Rapamycin | mTORC1 Inhibitor 9 | Rapamune (sirolimus) binds to the FKBP-12 to generate an immunosuppressive complex that binds and allosterically inhibits mTOR (PMID: 25261369). Rapamune (sirolimus) is FDA approved for the prevention of renal transplant rejection and for patients with lymphangioleiomyomatosis (FDA.gov). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03778996 | Phase II | Methoxsalen + Phenytoin + Sirolimus + SM88 | SM-88 as Maintenance Therapy for Advanced Ewing's Sarcoma Patients and as Salvage Therapy for Sarcoma Patients (HopES) | Active, not recruiting | USA | 0 |
NCT04720664 | Phase II | Methoxsalen + Phenytoin + Sirolimus + SM88 | Oral SM-88 in Patients With Metastatic HR+/HER2- Breast Cancer (OASIS) | Terminated | USA | 0 |
NCT03512756 | Phase II | Methoxsalen + Phenytoin + Sirolimus + SM88 Gemcitabine Fluorouracil Capecitabine | A Multi-Center Study of SM-88 in Subjects With Pancreatic Cancer | Terminated | USA | 0 |